Heterocyclic inhibitors of mct4
AssigneeVettore, LLC
InventorsKenneth Mark PARNELL, John MCCALL, Donna ROMERO
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Claims22
1-32. (canceled)
A method for treating a disorder chosen from a myeloproliferative neoplasm (MPN) or a myelodysplastic syndrome (MDS) in a subject in need thereof, comprising administering to the subject a compound of structural Formula II:
- or a salt thereof, wherein:
- L is chosen from a bond, methylene, and ethylene;
- W is chosen from
- Y is chosen from
- R2c is chosen from H, C1-C4alkoxy and C1-C4cycloalkoxy;
- R2d is chosen from null and C1-C4alkoxy;
- R2e is C1-C4alkyl;
- Z is chosen from
- n is 1 or 2;
- R4 and R5 are independently chosen from H and C1-C6alkyl, wherein R4 and R5 together comprise no more than 6 carbons and wherein at least one of R4 and R5 is C1-C6alkyl, or
- R4 and R5, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl or heterocycloalkyl ring;
- R6 is chosen from H and C1-C4alkyl;
- and
- R9 is chosen from halo, amino, and C1-C4alkoxy.
A method for treating a disorder chosen from a myeloproliferative neoplasm (MPN) or a myelodysplastic syndrome (MDS) in a subject in need thereof, comprising administering to the subject a compound of structural formula:
- or a salt thereof.
Dependencies are inferred from the claim text.